All In Biotech

Drug Trial Radar · NCT06996119

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Nov 5, 2028

Study completion Nov 5, 2028

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.

Conditions

  • Acute Myeloid Leukemia
  • Graft Versus Host Disease
  • Myelodysplastic Syndrome

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • BusulfanDrug

    Given IV

  • Computed TomographyProcedure

    Undergo chest CT

  • CyclophosphamideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • EmapalumabBiological

    Given IV

  • FludarabineDrug

    Given IV

  • Hematopoietic Cell TransplantationProcedure

    Given infusion

  • MelphalanDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Mycophenolate MofetilDrug

    Given IV or PO

  • Questionnaire AdministrationOther

    Ancillary studies

  • TacrolimusDrug

    Given IV or PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of grade 3 or higher adverse events (AEs)Time frame: From starting the first emapalumab dose to the first observation of a primary safety endpoint (PSE) event or day 28 post-hematopoietic cell transplantation (HCT), whichever comes first
  2. Incidence of severe infusion reactionTime frame: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
  3. Incidence of primary graft failureTime frame: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
  4. Non-relapse mortality (NRM)Time frame: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.